Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation

Bortezomib induces remissions in 30%-50% of patients with relapsed mantle cell lymphoma (MCL). Conversely, more than half of patients' tumors are intrinsically resistant to bortezomib. The molecular mechanism of resistance has not been defined. We generated a model of bortezomib-adapted subclon...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Pérez-Galán, Patricia, Mora-Jensen, Helena, Weniger, Marc A., Shaffer, Arthur L., Rizzatti, Edgar G., Chapman, Colby M., Mo, Clifton C., Stennett, Lawrence S., Rader, Christoph, Liu, Poching, Raghavachari, Nalini, Stetler-Stevenson, Maryalice, Yuan, Constance, Pittaluga, Stefania, Maric, Irina, Dunleavy, Kieron M., Wilson, Wyndham H., Staudt, Louis M., Wiestner, Adrian
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2011
Gaiak:
Lymphoid Neoplasia
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3031479/
https://ncbi.nlm.nih.gov/pubmed/20956803
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-02-269514
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak